Peripheral α‐helical CRF (9‐41) does not reverse stress‐induced mast cell dependent visceral hypersensitivity in maternally separated rats
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background Acute stress‐induced hypersensitivity to colorectal distention was shown to depend on corticotropin releasing factor (CRF)‐induced mast cell degranulation. At present it remains unclear whether CRF also induces chronic poststress activation of these cells. Accordingly, the objective of this study was to compare pre‐ and poststress CRF‐receptor antagonist treatment protocols for their ability to, respectively, prevent and reverse mast cell dependent visceral hypersensitivity in a rat model of neonatal maternal separation. Methods The visceromotor response to colonic distention was assessed in adult maternally separated and non‐handled rats before and at different time points after 1 h of water avoidance (WA). Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor‐antagonist α‐helical‐CRF (9‐41). Western blotting was used to assess mucosal protein levels of the mast cell protease RMCP‐2 and the tight junction protein occludin. Key Results In maternally separated, but not in non‐handled rats, WA induced chronic hypersensitivity (up to 30 days) to colorectal distention. Visceral hypersensitivity was prevented, but could not be reversed by administration of α‐helical‐CRF (9‐41). In contrast, however, the mast cell stabilizer doxantrazole reversed visceral hypersensitivity. Compared with vehicle‐treated rats, pre‐WA α‐helical‐CRF (9‐41) treated animals displayed higher mucosal RMCP‐2 and occludin levels. Conclusions & Inferences Water avoidance‐stress leads to persistent mast cell dependent visceral hypersensitivity in maternally separated rats, which can be prevented, but not reversed by blockade of peripheral CRF‐receptors. We conclude that persistent poststress mast cell activation and subsequent visceral hypersensitivity are not targeted by CRF‐receptor antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155 · cited 10×
“Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor-antagonist α-helical-CRF(9-41).”
BackgroundMethodInfluentialMast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome
Barbara, G., Wang, B., Stanghellini, V., de Giorgio, R., Cremon, C., Di Nardo, G., Trevisani, M., Campi, B., Geppetti, P., Tonini, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.039 · Cited by 783 · cited 10×
“Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor-antagonist α-helical-CRF(9-41).”
BackgroundMethodInfluentialPiche, T., Barbara, G., Aubert, P., Bruley des Varannes, S., Dainese, R., Nano, J. L., Cremon, C., Stanghellini, V, De Giorgio, R., Galmiche, J. P., et al. (2009) · Gut · doi:10.1136/gut.2007.140806 · Cited by 540
Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes
Dunlop, S. P., Hebden, J., Campbell, E., Naesdal, J., Olbe, L., Perkins, A. C., & Spiller, R. C. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00672.x · Cited by 476
Söderholm, J. D., Yang, P., Ceponis, P., Vohra, A., Riddell, R., Sherman, P. M., & Perdue, M. H. (2002) · Gastroenterology · doi:10.1053/gast.2002.36019 · Cited by 362
Buhner, S., Li, Q., Vignali, S., Barbara, G., De Giorgio, R., Stanghellini, V., Cremon, C., Zeller, F., Langer, R., Daniel, H., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.005 · Cited by 351
Early Life Risk Factors That Contribute to Irritable Bowel Syndrome in Adults: A Systematic Review
Chitkara, D. K., van Tilburg, M. A. L., Blois-Martin, N., & Whitehead, W. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01722.x · Cited by 303 · cited 10×
“Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor-antagonist α-helical-CRF(9-41).”
BackgroundMethodInfluentialPathophysiological Mechanisms of Stress-Induced Intestina Damage
Gareau, M., Silva, M., & Perdue, M. (2008) · Current Molecular Medicine · doi:10.2174/156652408784533760 · Cited by 268
Altered Rectal Perception in Irritable Bowel Syndrome Is Associated With Symptom Severity
Posserud, I., Syrous, A., Lindström, L., Tack, J., Abrahamsson, H., & Simrén, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.07.024 · Cited by 248
Söderholm, J. D., Yates, D. A., Gareau, M. G., Yang, P.-C., MacQueen, G., & Perdue, M. H. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00314.2002 · Cited by 243 · cited 10×
“Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor-antagonist α-helical-CRF(9-41).”
BackgroundMethodInfluentialIncreased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome
Coëffier, M., Gloro, R., Boukhettala, N., Aziz, M., Lecleire, S., Vandaele, N., Antonietti, M., Savoye, G., Bôle-Feysot, C., Déchelotte, P., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.700 · Cited by 185
Gareau, M. G., Jury, J., Yang, P. C., MacQueen, G., & Perdue, M. H. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000190577.62426.45 · Cited by 139 · cited 10×
“Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor-antagonist α-helical-CRF(9-41).”
BackgroundMethodInfluentialAntibodies to flagellin indicate reactivity to bacterial antigens in IBS patients
Schoepfer, A. M., Schaffer, T., Seibold‐schmid, B., Müller, S., & Seibold, F. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01166.x · Cited by 120
Teitelbaum, A. A., Gareau, M. G., Jury, J., Yang, P. C., & Perdue, M. H. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90210.2008 · Cited by 116 · cited 10×
“Rats were treated with the mast cell stabilizer doxantrazole and the CRF receptor-antagonist α-helical-CRF(9-41).”
BackgroundMethodInfluential
Cited by
Key role of CRF in the skin stress response system
Slominski, A. T., Zmijewski, M. A., Zbytek, B., Tobin, D. J., Theoharides, T. C., & Rivier, J. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1092 · Cited by 400
Impact of psychological stress on irritable bowel syndrome
Qin, H.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14126 · Cited by 398
Jennings, E. M., Okine, B. N., Roche, M., & Finn, D. P. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.003 · Cited by 318
The role of mast cells in functional GI disorders
Wouters, M. M., Vicario, M., & Santos, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309151 · Cited by 308
Self-citationPotential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions
Eller-Smith, O. C., Nicol, A. L., & Christianson, J. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00035 · Cited by 227
“Pre-treatment with a non-specific CRF antagonist, α-helical-CRF, also prevented stress-induced visceral hypersensitivity in NMS rats followingWAS, in aMC-dependent manner (van den Wijngaard et al., 2012).”
Background
Metadata
- Authors
- van den Wijngaard, R. M., Stanisor, O. I., van Diest, S. A., Welting, O., Wouters, M. M., de Jonge, W. J., & Boeckxstaens, G. E.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2011-11-30
- Volume
- 24
- Issue
- 3
- Pages
- 274
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W1576225633
- Cited by
- 49
- References
- 14
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.